<DOC>
	<DOCNO>NCT02867267</DOCNO>
	<brief_summary>The purpose study determine whether thymalfasin safe effective patient sepsis</brief_summary>
	<brief_title>The Efficacy Safety Ta1 Sepsis</brief_title>
	<detailed_description>Our previous study report 7-day treatment Ta 1 demonstrate positive active effect 28-day all-cause mortality augmentation mHLA-DR ( monocyte Human Leukocyte Antigen DR ) secondary endpoint . Therefore , intend verify find randomize , double-blind placebo-controlled clinical trial trail include subject impaired immunologic function .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Thymalfasin</mesh_term>
	<criteria>1 . Age ≥ 18 ≤85 2 . Signed informed consent sign 3 . Presence least one acute severe organ failure relate sepsis least one SOFA &gt; 1 4 . Infected focus confirm suspected satisfy least one following : 1. pathogenic microbe grow blood aseptic location 2. presence abscess partiallyinfected tissue 3. suspected infection identify least one follow evidence : leukocytes normal aseptic location organic perforation ( confirm image evidence , examination result intestinal content leak drainage ) Imaging evidence pneumonia accompany purulent secretion Related syndromes high infection risk ( cholangitis example ) 1 . History organ bone marrow transplantation 2 . Systemic autoimmune disease 3 . Under pregnancy suckle period 4 . Presence hematologic malignancy 5 . The patient incline stop cancel artificial intervention sustain life , word , abandon treatment 6 . The patient could die underlying disease within 28 day endstage 7 . The patient could die within 24 hour 8 . The patient undergone CPR past 72 hour neuromechanism fully recover 9 . The patient past 30 day undergone certain clinical drug instrument trial could affect immunity ( Xuebijing , ulinastatin CRRT ) 10 . The patient medical history allergy intolerance thymalfasin 11 . The source infection contain , example : infection hanlded surgical operation drainage 12 . The patient timely perform relevant test item 24 hour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>thymosin alpha 1 ; thymalfasin ; sepsis ; immunodepression</keyword>
</DOC>